Ractigen Therapeutics

About

Ractigen is an early-stage pharmaceutical company.

Nantong,Jiangsu,China
1 - 10

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: ¥110M
Industries: Health Care,Pharmaceutical
Founded date: Jan 1, 2016
Number Of Employee: 1 - 10
Operating Status: Active
Also Known As: 中美瑞康,中美瑞康核酸技术（南通）研究院有限公司

Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

¥110M $30M

Ractigen Therapeutics has raised a total of ¥110M $30M in funding over 2 rounds. Their latest funding was raised on Jan 27, 2022 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 27, 2022	Series A	$30M	5	SDIC Venture Capital	—	Detail
Feb 18, 2021	Series A	¥110M	3	GL Ventures	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

8

Ractigen Therapeutics is funded by 8 investors. SDIC Venture Capital and GL Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
SDIC Venture Capital	Yes	Series A
GL Ventures	Yes	Series A
China Singapore Suzhou Industrial Park Ventures	—	Series A
Eisai	—	Series A
Newzone Ventures	—	Series A
Xianghe Capital	—	Series A
Boyi Fund	—	Series A
Longmen Capital	—	Series A